|
1
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Perez EA, Romond EH, Suman VJ, Jeong JH,
Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA and
Wolmark N: Four-year follow-up of trastuzumab plus adjuvant
chemotherapy for operable human epidermal growth factor receptor
2-positive breast cancer: Joint analysis of data from NCCTG N9831
and NSABP B-31. J Clin Oncol. 29:3366–3373. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Early Breast Cancer Trialists'
Collaborative Group, . Polychemotherapy for early breast cancer: An
overview of the randomised trials. Lancet. 352:930–942. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sato M, Yao VJ, Arap W and Pasqualini R:
GRP78 signaling hub a receptor for targeted tumor therapy. Adv
Genet. 69:97–114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arap MA, Lahdenranta J, Mintz PJ, Hajitou
A, Sarkis AS, Arap W and Pasqualini R: Cell surface expression of
the stress response chaperone GRP78 enables tumor targeting by
circulating ligands. Cancer Cell. 6:275–284. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee AS: GRP78 induction in cancer:
Therapeutic and prognostic implications. Cancer Res. 67:3496–3499.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li J and Lee AS: Stress induction of
GRP78/BiP and its role in cancer. Curr Mol Med. 6:45–54. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
GonzalezGronow M, Cuchacovich M, Llanos C,
Urzua C, Gawdi G and Pizzo SV: Prostate cancer cell proliferation
in vitro is modulated by antibodies against
glucose-regulated protein 78 isolated from patient serum. Cancer
Res. 66:11424–11431. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rauschert N, Brändlein S, Holzinger E,
Hensel F, Müller-Hermelink HK and Vollmers HP: A new tumor-specific
variant of GRP78 as target for antibody-based therapy. Lab Invest.
88:375–386. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chinni SR, Falchetto R, GercelTaylor C,
Shabanowitz J, Hunt DF and Taylor DD: Humoral immune responses to
cathepsin D and glucose-regulated protein 78 in ovarian cancer
patients. Clin Cancer Res. 3:1557–1564. 1997.PubMed/NCBI
|
|
11
|
Papalas JA, Vollmer RT, GonzalezGronow M,
Pizzo SV, Burchette J, Youens KE, Johnson KB and Selim MA: Patterns
of GRP78 and MTJ1 expression in primary cutaneous malignant
melanoma. Mod Pathol. 23:134–143. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang LH, Yang XL, Zhang X, Cheng JX and
Zhang W: Association of elevated GRP78 expression with increased
astrocytoma malignancy via Akt and ERK pathways. Brain Res.
1371:23–31. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ni M, Zhang Y and Lee AS: Beyond the
endoplasmic reticulum: Atypical GRP78 in cell viability, signalling
and therapeutic targeting. Biochem J. 434:181–188. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Uramoto H, Sugio K, Oyama T, Nakata S, Ono
K, Yoshimastu T, Morita M and Yasumoto K: Expression of endoplasmic
reticulum molecular chaperone Grp78 in human lung cancer and its
clinical significance. Lung Cancer. 49:55–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hsu WM, Hsieh FJ, Jeng YM, Kuo ML, Tsao
PN, Lee H, Lin MT, Lai HS, Chen CN, Lai DM, et al: GRP78 expression
correlates with histologic differentiation and favorable prognosis
in neuroblastic tumors. Int J Cancer. 113:920–927. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dong D, Ko B, Baumeister P, Swenson S,
Costa F, Markland F, Stiles C, Patterson JB, Bates SE and Lee AS:
Vascular targeting and antiangiogenesis agents induce drug
resistance effector GRP78 within the tumor microenvironment. Cancer
Res. 65:5785–5791. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee E, Nichols P, Spicer D, Groshen S, Yu
MC and Lee AS: GRP78 as a novel predictor of responsiveness to
chemotherapy in breast cancer. Cancer Res. 66:7849–7853. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Paik S, Shak S, Tang G, Kim C, Baker J,
Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A
multigene assay to predict recurrence of tamoxifen-treated,
node-negative breast cancer. N Engl J Med. 351:2817–2826. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yarbro JW, Page DL, Fielding LP, Partridge
EE and Murphy GP: American Joint Committee on Cancer prognostic
factors consensus conference. Cancer. 86:2436–2446. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Iyalomhe GB and Imomoh PA: Ethics of
clinical trials. Niger J Med. 16:301–306. 2007.PubMed/NCBI
|
|
21
|
Cheang MC, Chia SK, Voduc D, Gao D, Leung
S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67
index, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cheang MC, Voduc D, Bajdik C, Leung S,
McKinney S, Chia SK, Perou CM and Nielsen TO: Basal-like breast
cancer defined by five biomarkers has superior prognostic value
than triple-negative phenotype. Clin Cancer Res. 14:1368–1376.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Weidner N, Cote RJ, Suster S and Weiss LM:
Modern Surgical Pathology. 2nd. Elsevier Saunders; Philadelphia,
PA: 2009, View Article : Google Scholar
|
|
24
|
Baptista MZ, Sarian LO, Vassallo J, Pinto
GA, Soares FA and de Souza GA: Prognostic significance of GRP78
expression patterns in breast cancer patients receiving adjuvant
chemotherapy. Int J Biol Markers. 26:188–196. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang L, Yang S, Liu J, Wang X, Ji J, Cao
Y, Lu K, Wang J and Gao Y: Expression of GRP78 predicts
taxane-based therapeutic resistance and recurrence of human gastric
cancer. Exp Mol Pathol. 96:235–241. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zheng YZ, Cao ZG, Hu X and Shao ZM: The
endoplasmic reticulum stress markers GRP78 and CHOP predict
disease-free survival and responsiveness to chemotherapy in breast
cancer. Breast Cancer Res Treat. 145:349–358. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hardy B, Raiter A, Yakimov M, Vilkin A and
Niv Y: Colon cancer cells expressing cell surface GRP78 as a marker
for reduced tumorigenicity. Cell Oncol (Dordr). 35:345–354. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Díaz Flaqué MC, Galigniana NM, Béguelin W,
Vicario R, Proietti CJ, Russo R, Rivas MA, Tkach M, Guzmán P, Roa
JC, et al: Progesterone receptor assembly of a transcriptional
complex along with activator protein 1, signal transducer and
activator of transcription 3 and ErbB-2 governs breast cancer
growth and predicts response to endocrine therapy. Breast Cancer
Res. 15:R1182013. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Boyle DP, McArt DG, Irwin G,
WilhelmBenartzi CS, Lioe TF, Sebastian E, McQuaid S, Hamilton PW,
James JA, Mullan PB, et al: The prognostic significance of the
aberrant extremes of p53 immunophenotypes in breast cancer.
Histopathology. 65:340–352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Coates AS, Millar EKA, O'Toole SA, Molloy
TJ, Viale G, Goldhirsch A, Regan MM, Gelber RD, Sun Z,
Castiglione-Gertsch M, et al: Prognostic interaction between
expression of p53 and estrogen receptor in patients with
node-negative breast cancer: Results from IBCSG trials VIII and IX.
Breast Cancer Res. 14:R1432012. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee E, Nichols P, Groshen S, Spicer D and
Lee AS: GRP78 as potential predictor for breast cancer response to
adjuvant taxane therapy. Int J Cancer. 128:726–731. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu KD, Huang AJ, Fan L, Li WF and Shao ZM:
Genetic variants in oxidative stress-related genes predict
chemoresistance in primary breast cancer: A prospective
observational study and validation. Cancer Res. 72:408–419. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Roller C and Maddalo D: The molecular
chaperone grp78/bip in the development of chemoresistance:
Mechanism and possible treatment. Front Pharmacol. 4:102013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Health Quality Ontario, . Gene expression
profiling for guiding adjuvant chemotherapy decisions in women with
early breast cancer: An evidence-based and economic analysis. Ont
Health Technol Assess Ser. 10:1–57. 2010.
|
|
35
|
van de Vijver MJ, He YD, van't Veer LJ,
Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C,
Marton MJ, et al: A gene-expression signature as a predictor of
survival in breast cancer. N Engl J Med. 347:1999–2009. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ: Panel members: Strategies for
subtypes - dealing with the diversity of breast cancer: Highlights
of the St. Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Carey LA, Dees EC, Sawyer L, Gatti L,
Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou
CM: The triple negative paradox: Primary tumor chemosensitivity of
breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rouzier R, Perou CM, Symmans WF, Ibrahim
N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P,
et al: Breast cancer molecular subtypes respond differently to
preoperative chemotherapy. Clin Cancer Res. 11:5678–5685. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Raiter A, Yerushalmi R and Hardy B:
Induction of cell surface GRP78 contributes to apoptosis in triple
negative breast cancer cells. Oncotarget. 5:11452–1163.
2014.PubMed/NCBI
|
